Chiesi Group signed an exclusive collaboration and license agreement with Arbor Biotechnologies to develop and potentially commercialize Arbor’s lipid‑nanoparticle delivered gene‑editing candidate ABO‑101 for primary hyperoxaluria type 1 (PH1), with the partnership potentially worth more than $2.1 billion. The deal includes joint work on the ongoing Phase I/II redePHine trial evaluating safety, tolerability and pharmacodynamics. ABO‑101 uses LNPs to deliver a Cas12i2 nuclease and a guide RNA to permanently knock out HAO1 in the liver, aiming to reduce oxalate overproduction in PH1 patients. The agreement gives Chiesi access to Arbor’s editing platform for additional liver‑directed programs under option terms. For Arbor, the collaboration provides a commercial and development partner to scale in vivo gene editing; for Chiesi, it marks a strategic entry into gene editing and rare disease therapeutics.